Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 6Sarcoma 2Gynecologic 2

Conditions

Recurrent Uterine Corpus Sarcoma 1Endometrial Adenocarcinoma 1

Interventions

Temozolomide 63Cyclophosphamide 55Radiotherapy 53Bevacizumab 50Doxorubicin 48Ifosfamide 33pazopanib 28fludarabine phosphate 28Etoposide 27Radiation 24Gemcitabine 24pembrolizumab 23Sirolimus 23Sunitinib 22Filgrastim 22Irinotecan 21Whole-Body Irradiation 20Peripheral Blood Stem Cell Transplantation 20Mycophenolic Acid 20Imatinib Mesylate 20Vincristine 19Magnetic Resonance Spectroscopy 18Sorafenib 16Methotrexate 16Busulfan 16Melphalan 15Carboplatin 15Docetaxel 14Cyclosporine 14temsirolimus 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Epothilones × Sarcoma × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

NCT01168232 2019-08-08

Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 10 charts
GynecologicSarcoma

Recurrent Uterine Corpus Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡